The FDA gave its approval to two combination AIDS drugs, making it more likely that patients in poor countries will have access to treatment through the U.S.' $15 billion emergency AIDS fund. Both pills combine two medicines into one pill to be taken once a day. Gilead Science's Truvada combines Viread and Emtriva and GlaxoSmithKline's Epzicom combines the company's HIV medicines Epivir and Ziagen.

Related Summaries